Search ( Ctrl + / )
Iovance Biotherapeutics, Inc.
IOVANASDAQ
IOVANASDAQ
IOVANASDAQ
| Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | |
|---|---|---|---|---|---|---|---|---|
| Statement Date | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 9/30/2022 |
| Revenue | 58.55M | 31.11M | 715,000.00 | 482,000.00 | 469,000.00 | 238,000.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.82M | 36.75M | 12.54M | 14.08M | 4.34M | 2.05M | 5.70M | 0.00 |
| Gross Profit | 18.73M | -5.64M | -11.82M | -13.60M | -3.87M | -1.81M | -5.70M | 0.00 |
| Gross Profit Ratio | 0.32 | -0.18 | -16.53 | -28.21 | -8.25 | -7.61 | 0.00 | 0.00 |
| Research and Development Expenses | 68.25M | 62.08M | 79.78M | 87.47M | 87.53M | 86.35M | 82.73M | 72.50M |
| General and Administrative Expenses | 0.00 | 0.00 | 8.26M | 0.00 | 26.96M | 21.93M | 28.12M | 27.89M |
| Selling and Marketing Expenses | 0.00 | 0.00 | 17.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 107.80M | 96.27M | 105.90M | 107.66M | 114.49M | 108.27M | 110.86M | 100.40M |
| Cost and Expenses | 147.62M | 133.02M | 118.44M | 121.74M | 118.83M | 110.32M | 110.86M | 100.40M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.49M | 777,000.00 |
| Depreciation and Amortization | 0.00 | 10.86M | 9.91M | 9.71M | 9.88M | 7.84M | 5.70M | 5.20M |
| EBITDA | -89.07M | -91.05M | -107.82M | -111.54M | -118.36M | -110.09M | -110.86M | -93.64M |
| EBITDA Ratio | -1.52 | -2.93 | -150.79 | -231.41 | -252.37 | -462.55 | 0.00 | 0.00 |
| Operating Income | -89.07M | -101.91M | -117.72M | -121.26M | -118.36M | -110.09M | -110.86M | -100.40M |
| Operating Income Ratio | -1.52 | -3.28 | -164.65 | -251.57 | -252.37 | -462.55 | 0.00 | 0.00 |
| Total Other Income Expenses | 4.01M | 3.36M | 3.34M | 3.12M | 3.36M | 3.08M | 3.49M | 777,000.00 |
| Income Before Tax | -85.06M | -98.56M | -114.38M | -118.14M | -115.00M | -107.01M | -107.37M | -99.62M |
| Income Before Tax Ratio | -1.45 | -3.17 | -159.98 | -245.10 | -245.21 | -449.60 | 0.00 | 0.00 |
| Income Tax Expense | -1.52M | -1.46M | -1.41M | -1.76M | -1.24M | -477,000.00 | -3.49M | 0.00 |
| Net Income | -83.54M | -97.10M | -112.98M | -116.38M | -113.76M | -106.53M | -103.88M | -99.62M |
| Net Income Ratio | -1.43 | -3.12 | -158.01 | -241.45 | -242.56 | -447.60 | 0.00 | 0.00 |
| EPS | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.49 | -0.63 |
| Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | |
|---|---|---|---|---|---|---|---|---|
| Statement Date | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 9/30/2022 |
| Revenue | 58.55M | 31.11M | 715,000.00 | 482,000.00 | 469,000.00 | 238,000.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.82M | 36.75M | 12.54M | 14.08M | 4.34M | 2.05M | 5.70M | 0.00 |
| Gross Profit | 18.73M | -5.64M | -11.82M | -13.60M | -3.87M | -1.81M | -5.70M | 0.00 |
| Gross Profit Ratio | 0.32 | -0.18 | -16.53 | -28.21 | -8.25 | -7.61 | 0.00 | 0.00 |
| Research and Development Expenses | 68.25M | 62.08M | 79.78M | 87.47M | 87.53M | 86.35M | 82.73M | 72.50M |
| General and Administrative Expenses | 0.00 | 0.00 | 8.26M | 0.00 | 26.96M | 21.93M | 28.12M | 27.89M |
| Selling and Marketing Expenses | 0.00 | 0.00 | 17.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 107.80M | 96.27M | 105.90M | 107.66M | 114.49M | 108.27M | 110.86M | 100.40M |
| Cost and Expenses | 147.62M | 133.02M | 118.44M | 121.74M | 118.83M | 110.32M | 110.86M | 100.40M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.49M | 777,000.00 |
| Depreciation and Amortization | 0.00 | 10.86M | 9.91M | 9.71M | 9.88M | 7.84M | 5.70M | 5.20M |
| EBITDA | -89.07M | -91.05M | -107.82M | -111.54M | -118.36M | -110.09M | -110.86M | -93.64M |
| EBITDA Ratio | -1.52 | -2.93 | -150.79 | -231.41 | -252.37 | -462.55 | 0.00 | 0.00 |
| Operating Income | -89.07M | -101.91M | -117.72M | -121.26M | -118.36M | -110.09M | -110.86M | -100.40M |
| Operating Income Ratio | -1.52 | -3.28 | -164.65 | -251.57 | -252.37 | -462.55 | 0.00 | 0.00 |
| Total Other Income Expenses | 4.01M | 3.36M | 3.34M | 3.12M | 3.36M | 3.08M | 3.49M | 777,000.00 |
| Income Before Tax | -85.06M | -98.56M | -114.38M | -118.14M | -115.00M | -107.01M | -107.37M | -99.62M |
| Income Before Tax Ratio | -1.45 | -3.17 | -159.98 | -245.10 | -245.21 | -449.60 | 0.00 | 0.00 |
| Income Tax Expense | -1.52M | -1.46M | -1.41M | -1.76M | -1.24M | -477,000.00 | -3.49M | 0.00 |
| Net Income | -83.54M | -97.10M | -112.98M | -116.38M | -113.76M | -106.53M | -103.88M | -99.62M |
| Net Income Ratio | -1.43 | -3.12 | -158.01 | -241.45 | -242.56 | -447.60 | 0.00 | 0.00 |
| EPS | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.49 | -0.63 |